The estimated Net Worth of Aharon Schwartz is at least 181 千$ dollars as of 3 January 2023. Aharon Schwartz owns over 110,000 units of Protalix BioTherapeutics stock worth over 180,960$ and over the last 7 years he sold PLX stock worth over 0$. In addition, he makes 0$ as Independent Director at Protalix BioTherapeutics.
Aharon has made over 3 trades of the Protalix BioTherapeutics stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 110,000 units of PLX stock worth 156,200$ on 3 January 2023.
The largest trade he's ever made was buying 112,200 units of Protalix BioTherapeutics stock on 26 November 2018 worth over 437,580$. On average, Aharon trades about 28,620 units every 150 days since 2018. As of 3 January 2023 he still owns at least 174,000 units of Protalix BioTherapeutics stock.
You can see the complete history of Aharon Schwartz stock trades at the bottom of the page.
Dr. Aharon Schwartz, Ph.D. is the Independent Director of the Protalix Biotherapeutics Inc., He has served as our director since November 2014. He retired from Teva in 2011 where he served in a number of positions from 1975 through 2011, the most recent being Vice President, Head of Teva Innovative Ventures from 2008. Dr. Schwartz is currently chairman of the board of directors of BiolineRx Ltd. (NASDAQ:BLRX, TASE:BLRX) and a member of the board of directors of Barcode Ltd and Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX). He also works as an independent consultant. From January 2013 through November 2017, he served as a member of the board of directors of Alcobra Ltd. (NASDAQ:ADHD), which is now called Arcturus Therapeutics Ltd. Dr. Schwartz received his Ph.D. in organic chemistry in 1978 from the Weizmann Institute of Science, his M.Sc. in organic chemistry from the Technion and a B.Sc. in chemistry and physics from the Hebrew University of Jerusalem. Dr. Schwartz received a second Ph.D. in 2014 from the Hebrew University of Jerusalem in the history and philosophy of science. Schwartz’s qualifications to serve on our Board of Directors include his years of experience in life science companies.
Aharon Schwartz is 75, he's been the Independent Director of Protalix BioTherapeutics since 2014. There are no older and 13 younger executives at Protalix BioTherapeutics.
Aharon's mailing address filed with the SEC is Rehovot, Israel.
Over the last 18 years, insiders at Protalix BioTherapeutics have traded over 46,705,936$ worth of Protalix BioTherapeutics stock and bought 4,403,619 units worth 4,673,005$ . The most active insiders traders include Phillip Md Et Al Frost Gamm...、Capital Management Lp Camber、Ltd Bio Cell. On average, Protalix BioTherapeutics executives and independent directors trade stock every 88 days with the average trade being worth of 404,231$. The most recent stock trade was executed by Dror Bashan on 19 October 2023, trading 64,516 units of PLX stock currently worth 90,322$.
protalix is a publicly traded, clinical stage biopharmaceutical company (nyse, tase: plx) focused on the development and commercialization of recombinant therapeutic proteins using its proprietary procellex™ plant cell culture protein expression system. procellex provides a unique platform on which we have established a pipeline of proprietary and biosimilar versions of recombinant therapeutic proteins, relying upon known biological mechanisms of action. protalix's lead product, taliglucerase-alfa is an enzyme replacement therapy for the treatment of gaucher´s disease. protalix has concluded phase iii studies for this drug and is currently undergoing fda review. treatment is currently being provided by protalix to gaucher patients under clinical studies and companionate programs to hundreds of patients worldwide. this product has been licensed to pfizer. protalix's pipeline includes multiple therapeutic protein candidates including: acetylcholinesterase (biodefense); alfa‐galactosidase
Protalix BioTherapeutics executives and other stock owners filed with the SEC include: